Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.
about
Biomarkers and biometric measures of adherence to use of ARV-based vaginal ringsMaraviroc: a review of its use in HIV infection and beyondPreventing HIV infection: pre-exposure and postexposure prophylaxisCCR5 antagonism in HIV infection: current concepts and future opportunitiesAntiretroviral pharmacology in mucosal tissuesEffects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialImmune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV preventionPharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.Current perspectives in HIV post-exposure prophylaxis.Models for predicting effective HIV chemoprevention in womenConcentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesThe male genital tract is not a pharmacological sanctuary from efavirenz.Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens.A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.The use of preexposure treatments for HIV prophylaxisHIV prevention by oral preexposure prophylaxis.HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.Pharmacokinetics of antiretrovirals in mucosal tissuePharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 PreventionSingle- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.Does ART prevent HIV transmission among MSM?Antiviral agents and HIV prevention: controversies, conflicts, and consensus.Pre-exposure prophylaxis for HIV prevention: how to predict success.Antiretrovirals and safer conception for HIV-serodiscordant couplesNext-generation oral preexposure prophylaxis: beyond tenofovirLack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissuesDolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.Antiretroviral bioanalysis methods of tissues and body biofluids.HIV PrEP Trials: The Road to Success.Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherenceExpression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.Drug safety evaluation of maraviroc for the treatment of HIV infection.The development of rectal microbicides for HIV prevention.An overview of antiretroviral pre-exposure prophylaxis of HIV infection.Strategies to limit immune-activation in HIV patients.
P2860
Q26753097-9F8AF010-5347-44D5-899B-1743CE8B3DC9Q26778504-0A8ABA9E-6920-4B27-B9C1-E54E7FC6A2F8Q26828445-84EF1392-3231-432C-8635-CAAEB8395BD4Q26865457-5333117B-6D49-483B-B6C4-4CB78E560C2FQ27014675-6CC1F9C1-750B-4CF8-AA48-456C00E453FEQ28552729-C542AE80-9779-4CBD-8409-E676FA3878AEQ30362489-80AEA266-B60B-4E89-A112-AD981554F45AQ33593633-BAE0E9EF-6C2A-4E76-AC2F-D64817BB2C48Q33643626-86158FBE-FC62-471B-A6E8-E64F7F490B9AQ33769971-77FF0A8D-F46C-46E5-8B2E-0BB4B735A373Q33888718-CB3BE7D6-5FB6-4636-8576-2CE440B6BF0AQ34360012-BC6E07DF-D7AF-4AE5-85DF-DBCED3FFAE0DQ34434815-CCC77C35-9D57-4B06-ADC0-2E0934BBFD0AQ35102285-579A0BE5-4286-464F-A855-90F0782EA422Q35270776-C727CD5B-D161-4265-AECD-DF6FF6BCED13Q35432739-3111C961-FFA7-4A04-96DC-8ED90C436DDEQ35548422-140D10E2-F662-44BA-9557-2C7B9F9B6BEFQ35588077-34C0AF27-18B1-4429-BE2F-E1C1DC0B044AQ35667426-5C4DBE1D-68EE-4D14-87F0-69CE7D1D502CQ35760180-04E902E1-A559-4A54-AC4A-28FFA04E8946Q35765743-412CDF46-3619-461D-A981-8B3895068256Q35794988-5CF6CCBB-688F-476F-B7C5-1B40473C6418Q35838594-7F85778F-A1A8-4133-9AAF-61F25B09851FQ36143276-656F6845-FDD4-425E-B54B-64B044BCA307Q36279339-30A9B81B-E632-4723-BC24-FB7D5DBD9B9AQ36403679-7663FEDE-17D3-4F52-9A47-01322FE692F7Q36836680-63714306-284D-49D0-9FC6-A2487EEB28A7Q36839567-632792F7-691D-4C3D-BE55-C9E68A3BF346Q36964167-205BEBA3-2DD4-4AA1-8C23-CCA180F9FD43Q37067126-DB31A3D9-84CB-4EA0-9D34-EE7FABA5EA1CQ37123335-C927328B-EA13-4763-8B36-60767A343DB7Q37246359-6EAA65A5-0366-40ED-894A-282E99DBA6CDQ37332868-917E41DB-5D08-42D7-86C6-69731EA791B0Q37438644-72FBA7C9-04C9-472B-97B4-4EA9C629A7E9Q37637073-96680018-ECDA-4765-9E5A-C0D37672EFDAQ37716218-075C33A0-8F93-4A57-9747-86A6E15BF40EQ37961188-85F2F61D-E356-4F3B-83F6-2EC9FB965AE1Q38165222-26D103D5-B771-41C3-A329-C927C97CFA68Q38196410-DDABC9D5-371D-49B8-9418-F798178098C3Q38985926-3A963BE5-1DBD-4064-A6D2-69343966061A
P2860
Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@ast
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@en
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@nl
type
label
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@ast
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@en
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@nl
prefLabel
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@ast
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@en
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@nl
P2093
P2860
P356
P1476
Single and multiple dose pharm ...... e of healthy HIV-negative men.
@en
P2093
Angela D M Kashuba
Heather M Asher Prince
Julie B Dumond
Kevin C Brown
Kristine B Patterson
Melissa B Spacek
Paris E Heidt
Stephanie A Malone
P2860
P304
P356
10.1093/INFDIS/JIR059
P407
P577
2011-05-01T00:00:00Z